Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avi BioPharma, Inc.
Avi BioPharma presents initial positive results on hepatitis C virus candidate
June 2nd, 2006
Avi BioPharma, Inc., (AVII) presented initial data from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection at the International Conference on Antiviral Research (ICAR) annual meeting. Avi's presentation titled "Avi-4065, An Antisense Approach to Active HCV Infection: Preclinical and Clinical Evaluation" was presented by Patrick L. Iversen, PhD, Avi's senior vice president of research and development. The second phase of the trial has been designed to assess the safety, tolerability, pharmacokinetics (PK) and viral and clinical response to treatment with Avi's proprietary Neugene antisense...
Source: Medicine & Law Weekly (2006-06-02)
|
